171 related articles for article (PubMed ID: 26681397)
1. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer.
Ryall KA; Kim J; Klauck PJ; Shin J; Yoo M; Ionkina A; Pitts TM; Tentler JJ; Diamond JR; Eckhardt SG; Heasley LE; Kang J; Tan AC
BMC Genomics; 2015; 16 Suppl 12(Suppl 12):S2. PubMed ID: 26681397
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.
Fink LS; Beatty A; Devarajan K; Peri S; Peterson JR
Mol Cancer Ther; 2015 Jan; 14(1):298-306. PubMed ID: 25344583
[TBL] [Abstract][Full Text] [Related]
3. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potential of ERK5 targeting in triple negative breast cancer.
Ortiz-Ruiz MJ; Álvarez-Fernández S; Parrott T; Zaknoen S; Burrows FJ; Ocaña A; Pandiella A; Esparís-Ogando A
Oncotarget; 2014 Nov; 5(22):11308-18. PubMed ID: 25350956
[TBL] [Abstract][Full Text] [Related]
5. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
6. Chk1 as a new therapeutic target in triple-negative breast cancer.
Albiges L; Goubar A; Scott V; Vicier C; Lefèbvre C; Alsafadi S; Commo F; Saghatchian M; Lazar V; Dessen P; Delaloge S; André F; Quidville V
Breast; 2014 Jun; 23(3):250-8. PubMed ID: 24636978
[TBL] [Abstract][Full Text] [Related]
7. Circular RNA circ-ERBB2 Elevates the Warburg Effect and Facilitates Triple-Negative Breast Cancer Growth by the MicroRNA 136-5p/Pyruvate Dehydrogenase Kinase 4 Axis.
Huang Y; Zheng S; Lin Y; Ke L
Mol Cell Biol; 2021 Sep; 41(10):e0060920. PubMed ID: 34370552
[TBL] [Abstract][Full Text] [Related]
8. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
10. TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis.
Hu J; Lai Y; Huang H; Ramakrishnan S; Pan Y; Ma VWS; Cheuk W; So GYK; He Q; Geoffrey Lau C; Zhang L; Cho WCS; Chan KM; Wang X; Rebecca Chin Y
Br J Cancer; 2022 Jan; 126(1):57-71. PubMed ID: 34718356
[TBL] [Abstract][Full Text] [Related]
11. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
12. Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data.
Ryall KA; Shin J; Yoo M; Hinz TK; Kim J; Kang J; Heasley LE; Tan AC
Bioinformatics; 2015 Dec; 31(23):3799-806. PubMed ID: 26206305
[TBL] [Abstract][Full Text] [Related]
13. Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells.
Lin W; Huang J; Yuan Z; Feng S; Xie Y; Ma W
Sci Rep; 2017 May; 7(1):2022. PubMed ID: 28515445
[TBL] [Abstract][Full Text] [Related]
14. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
Cheng L; Schneider BP; Li L
J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
[TBL] [Abstract][Full Text] [Related]
15. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
[TBL] [Abstract][Full Text] [Related]
16. An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer.
van der Noord VE; McLaughlin RP; Smid M; Foekens JA; Martens JWM; Zhang Y; van de Water B
Sci Rep; 2019 Sep; 9(1):13308. PubMed ID: 31527768
[TBL] [Abstract][Full Text] [Related]
17. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor β-activated kinase 1 inhibitor suppresses the proliferation in triple-negative breast cancer through TGF-β/TGFR pathway.
Zhang L; Fu Z; Li X; Tang H; Luo J; Zhang D; Zhuang Y; Han Z; Yin M
Chem Biol Drug Des; 2017 Sep; 90(3):450-455. PubMed ID: 28224764
[TBL] [Abstract][Full Text] [Related]
19. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer.
Hsu YH; Yao J; Chan LC; Wu TJ; Hsu JL; Fang YF; Wei Y; Wu Y; Huang WC; Liu CL; Chang YC; Wang MY; Li CW; Shen J; Chen MK; Sahin AA; Sood A; Mills GB; Yu D; Hortobagyi GN; Hung MC
Cancer Res; 2014 Sep; 74(17):4822-35. PubMed ID: 24970481
[TBL] [Abstract][Full Text] [Related]
20. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
